Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders that can continue into adulthood. This condition entails several recurring problems,…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Renal inflammation associated with SLE, also known as LN, is among the most serious manifestations of the disease. Until recently, no therapy was specifically approved for LN. Most treatments are…
Psychiatric disorders such as anxiety, posttraumatic stress disorder (PTSD), and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists…
Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) therapy…
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will…